chartexchange

Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire Inc. | Nov 5, 2026 7:30 AM EST

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027

Read original article